Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a study titled ‘Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy.’ The study aims to assess the risk of pregnancy and infant outcomes in women with migraines who are exposed to rimegepant during pregnancy compared to those not exposed to the drug. This research is significant as it seeks to understand the safety and implications of using rimegepant, a migraine medication, during pregnancy.
The intervention being tested is the drug Rimegepant, which is used to treat migraines. The study compares outcomes in women exposed to Rimegepant with those exposed to other migraine medications and those without migraine exposure.
This observational study follows a cohort model with a retrospective time perspective. It does not involve any allocation or masking, focusing primarily on understanding outcomes related to drug exposure during pregnancy.
The study began on December 15, 2021, and is currently recruiting participants. The last update was submitted on July 8, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
For Pfizer, the study’s outcomes could influence investor sentiment and stock performance, particularly if the results impact the perceived safety of Rimegepant. Competitors in the migraine medication market may also be affected as safety profiles are a critical factor in drug selection.
The study is ongoing, and further details are available on the ClinicalTrials portal.